NeuroThera closes first C$2.7M tranche of private placement
What's the deal? NeuroThera LabsDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotech listed on the TSX Venture Exchange, has closed the first tranche of a non-brokered private placement, raising C$2,700,000. The company sold 22,500,000 units at C$0.12 each.
What's the endgame? Each unit pairs one common share with a warrant to buy another share at US$0.115 (C$0.16) until August 12, 2029. NeuroThera plans to use the net proceeds for working capital, evaluating prospective transactions, and repaying debt owed to its majority owner, SciSparcDealroom has a profile for this one. Try Dealroom →.
Who's behind it? NeuroThera is a majority-owned subsidiary of SciSparc, developing therapeutics for central nervous system disorders and other underserved conditions. It paid C$222,750 in finder's fees plus 2,812,500 common shares to an arm's length party.
What's next? The warrants carry an acceleration provision tied to a potential Nasdaq listing: if NeuroThera's securities are approved for trading there, the company can accelerate the expiry of half the unexercised warrants. The offering still requires final approval from the TSX Venture Exchange.
The signal: The raise is a modest one — roughly $1.9M — landing in the lower quartile of comparable rounds. For a small-cap clinical-stage biotech, the tranche buys runway and a path toward a larger US listing rather than a growth war chest.
Read more: The Newswire
Image credit: jurvetson
